<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04708288</url>
  </required_header>
  <id_info>
    <org_study_id>2680</org_study_id>
    <nct_id>NCT04708288</nct_id>
  </id_info>
  <brief_title>A PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, POST MARKET OBSERVATIONAL STUDY TO EVALUATE THE SAFETY AND CLINICAL PERFORMANCE OF THE ARCHIMEDES BIODEGRADABLE BILIARY AND PANCREATIC STENT</brief_title>
  <acronym>AM GI Registry</acronym>
  <official_title>A PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, POST MARKET OBSERVATIONAL STUDY TO EVALUATE THE SAFETY AND CLINICAL PERFORMANCE OF THE ARCHIMEDES BIODEGRADABLE BILIARY AND PANCREATIC STENT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>QualiMed Innovative Medizinprodukte GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>QualiMed Innovative Medizinprodukte GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Significant experience with biodegradable materials has been reported in the orthopedic&#xD;
      literature; in particular; biodegradable stents have been used in the endovascular and&#xD;
      urologic epithelium. Stents are typically made from polymeric materials including Polylactic&#xD;
      Acid (PLA), Polyglycolide (PGA), Polydioxanone (PDO), Polyethyleneglycol (PEG),&#xD;
      Polycaprolactone (PCL), etc., which have been cleared or approved by the FDA and CE-marked as&#xD;
      drug carriers, sutures, and bone fixatives. The material is degraded by hydrolysis in, e.g.,&#xD;
      lactic acid, which is removed from the body by normal metabolic pathways. In the field of&#xD;
      gastroenterology, these stents were first introduced in patients with an esophageal stenosis&#xD;
      with encouraging results, although esophageal hyperplasia was a frequently encountered&#xD;
      complication.&#xD;
&#xD;
      For biliary applications, biodegradable stents have been evaluated in several in-vitro and&#xD;
      animal studies that demonstrated that the stents were safe and well tolerated. These stents&#xD;
      provided an adequate radial force and resulted in complete stricture resolution within&#xD;
      several months. The stents did not show any signs of biliary hyperplasia or integration in&#xD;
      the epithelium. Moreover, they seem to have a self-clearing effect on attached biofilm as the&#xD;
      outer layer sloughs during the degradation process similarly to the exfoliation of human&#xD;
      skin. Also, the stent could be removed from the bile duct, thus offering the possibility of&#xD;
      extraction if necessary at various times after implantation.&#xD;
&#xD;
      In 2010, Petryl was the first to use a biodegradable stent in the human bile duct. A stent&#xD;
      was successfully placed using percutaneous transhepatic cholangiograpy in two patients with a&#xD;
      postsurgical intrahepatic biliary stricture. Transient cholangitis was the only complication&#xD;
      encountered and during the two years of follow-up, the bile duct remained patent.&#xD;
&#xD;
      Later, Mauri et al. presented in 2013 and 2016 results of a 107 patient study on a&#xD;
      polydioxanone biodegradable biliary stent. The results have been published in the Journal of&#xD;
      the European Society of Radiology. The authors concluded that percutaneous placement of a&#xD;
      biodegradable biliary stent is a feasible and safe strategy to treat benign biliary&#xD;
      strictures refractory to standard bilioplasty, with promising results in the mid-term period.&#xD;
&#xD;
      Prior to this study, the ARCHIMEDES device was assessed in the ARCHIMEDES Investigational&#xD;
      study which has completed enrolment with 53 patients included, and the results are not yet&#xD;
      published. In this study approximately half the stents were deployed in the bile duct (53%)&#xD;
      and half in the pancreatic duct. All 53 patients have either completed, exited, or no longer&#xD;
      have the study device. No patient remains in the study with a stent in place during the time&#xD;
      of the last patient follow-ups. The study concluded without any device-related SAE. Bilirubin&#xD;
      was reduced by 25.6%, which exceeded the &gt;20% clinical success criterion, quality of life&#xD;
      score improved from 3.7 to 7.9, procedural success was rated 1.4 (good to excellent), and&#xD;
      technical success was achieved in all 53 patients.&#xD;
&#xD;
      Data from the ARCHIMEDES Investigational study was used for CE Mark approval, which was&#xD;
      obtained in June 2018.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 22, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Safety data of the procedure</measure>
    <time_frame>24 months</time_frame>
    <description>Number of patients with adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical performance of the procedure</measure>
    <time_frame>24 months</time_frame>
    <description>Number of patients with better synthomatology</description>
  </primary_outcome>
  <enrollment type="Anticipated">198</enrollment>
  <condition>Obstructed Biliary and Pancreatic Duct</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ARCHIMEDES Biodegradable Biliary and Pancreatic Stent</intervention_name>
    <description>Pts that will receive ARCHIMEDES Biodegradable Biliary and Pancreatic Stent</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients that will respect the inlcusion criteria will be enrolled in the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient eligible for implantation of a pancreatic or billiary stent prior to&#xD;
             participate in the study and according to current guidelines&#xD;
&#xD;
          -  Patient has provided a signed and dated informed consent (according to the laws and&#xD;
             regualtions of the country in which the observational study is conducted)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 y&#xD;
&#xD;
          -  Inability to understand the purpose of the study or refusal to cooperate&#xD;
&#xD;
          -  Not available for routine follow-up visits&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Currently participating in a confounding trial before reaching first endpoint.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Volker Wenke, MSc</last_name>
    <phone>+49 173 7211332</phone>
    <email>wenke@qualimed.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Manfred Guelcher, MSc</last_name>
    <phone>+4941716578200</phone>
    <email>guelcher@qualimed.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Erasme University Hospital</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacques Devière, MD</last_name>
      <email>Jacques.Deviere@erasme.ulb.ac.be</email>
    </contact>
    <contact_backup>
      <last_name>Mia Persoons</last_name>
      <phone>+322555 3016</phone>
      <email>Mia.Persoons@erasme.ulb.ac.be</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>HUS Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00290</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leena Kylänpää, MD</last_name>
      <email>leena.kylanpaa@hus.fi</email>
    </contact>
    <contact_backup>
      <last_name>Heidi Asmundela, MD</last_name>
      <email>ext-heidi.asmundela@hus.fi</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hôpital Beaujon, AP-HP</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frédéric Prat, MD</last_name>
      <phone>00 33 1 40875663</phone>
      <email>frederic.prat@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges-Pompidou HEGP</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Enrique Pérez-Cuadrado Robles, MD</last_name>
      <email>kikemurcia@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40217</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Horst Neuhaus, MD</last_name>
      <email>Horst.Neuhaus@evk-duesseldorf.de</email>
    </contact>
    <contact_backup>
      <last_name>Biljana Dimitrijevic, PhD</last_name>
      <phone>+49 (0)211919483 601</phone>
      <email>Biljana.Dimitrijevic@evk-duesseldorf.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinik Klinikum rechts der Isar der TU</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christoph Schlag, MD</last_name>
      <email>christoph.schlag@mri.tum.de</email>
    </contact>
    <contact_backup>
      <last_name>Julia Horstmann</last_name>
      <phone>+49894140 6394</phone>
      <email>Julia.Horstmann@mri.tum.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Emek Medical Center</name>
      <address>
        <city>Afula</city>
        <zip>1834111</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ian M. Gralnek, MD</last_name>
      <phone>+972046495545</phone>
      <email>ian_gr@clalit.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Inbal Lasry Reish, PhD</last_name>
      <phone>+9720528877977</phone>
      <email>inbal_la@clalit.org.il</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Endoscopy Unit, Humanitas Research Hospital</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Repici, MD</last_name>
      <phone>+39282247493</phone>
      <email>alessandro.repici@humanitas.it</email>
    </contact>
    <investigator>
      <last_name>Andrea Anderloni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alessandro Fugazza, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AUSL Romagna Ospedale Morgagni - Pierantoni</name>
      <address>
        <city>Forlì</city>
        <zip>47121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carlo Fabbri, MD</last_name>
      <email>carlo.fabbri@auslromagna.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCBM - Campus Bio-Medico University</name>
      <address>
        <city>Roma</city>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesco Di Matteo, MD</last_name>
      <email>f.dimatteo@unicampus.it</email>
    </contact>
    <contact_backup>
      <last_name>Maria Gulia Nigro, MD</last_name>
      <phone>+3906225418058</phone>
      <email>Ma.Nigro@unicampus.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario Agostino Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guido Costamagna, MD</last_name>
      <email>guido.costamagna@unicatt.it</email>
    </contact>
    <contact_backup>
      <last_name>Carolina Gualtieri</last_name>
      <phone>+390630156580</phone>
      <email>carolina.gualtieri@policlinicogemelli.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Medical Center Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Samo Plut, MD</last_name>
      <email>samo.plut@kclj.si</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alberto Álvarez Delgado, MD</last_name>
      <phone>+34 696351845</phone>
      <email>aalvarezd@saludcastillayleon.es</email>
    </contact>
    <contact_backup>
      <last_name>ALEJANDRO NUÑEZ Alonso, PhD</last_name>
      <phone>+34 923291100</phone>
      <phone_ext>55400</phone_ext>
      <email>alnual@saludcastillayleon.es</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Slovenia</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 8, 2021</study_first_submitted>
  <study_first_submitted_qc>January 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2021</study_first_posted>
  <last_update_submitted>June 10, 2021</last_update_submitted>
  <last_update_submitted_qc>June 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

